Neurology’s denial rate of 20–30% is nearly triple the outpatient specialty average — and unlike most specialties where high denial volume means lots of small corrections, neurology denials involve procedures and infusions where a single denied claim is $5,000–$25,000. The math is unforgiving: a neurology practice submitting $200,000/month in claims with a 25% denial rate has $50,000/month in claims requiring active management, with an average recovery timeline of 45–90 days per denied claim.
Three billing problems drive the majority of neurology denials. All three are preventable.
Problem 1: Prior Authorization on High-Value Procedures
Prior authorization is required for virtually every high-value procedure in neurology: EEG, EMG/nerve conduction studies, evoked potentials, transcranial magnetic stimulation, botulinum toxin injections for migraine or spasticity, MS infusion therapy, and advanced imaging. The auth requirement varies by payer, changes frequently, and is enforced strictly — a service rendered without valid prior auth generates a CO-15 denial on a claim that may be worth $8,000–$25,000.
The compounding problem: when a CO-15 denial arrives on a $14,000 infusion claim, the retroactive auth process begins. Most payers allow retrospective authorization, but approval rates are lower than prospective rates, response times are 30–90 days, and some payers specifically exclude certain procedures from retroactive consideration.
A neurology billing specialist maintains a procedure-by-payer authorization matrix that is updated as payer policies change, tracks every pending and active authorization by patient and procedure, and flags renewals 14 days before expiration. The goal is zero CO-15 denials — each one represents a high-value revenue risk that shouldn’t exist.
Problem 2: EEG and EMG Coding Complexity
Electroencephalography and electromyography have distinct code sets with professional and technical component modifiers that must be applied correctly based on who performs and interprets each component:
| Procedure | Code | Component Rules |
|---|---|---|
| Routine EEG (awake/drowsy) | 95816 | Global (professional + technical) if neurologist owns equipment; -26 if interpretation only |
| EEG with sleep | 95822 | Same component rules as 95816 |
| EMG (needle) | 95860–95872 | Billed per muscle group; professional component; number of muscles documented must match billed codes |
| Nerve conduction studies | 95907–95913 | Billed by number of studies; both sensory and motor components reported separately |
| Evoked potentials | 95925–95930 | Multiple codes by modality; may require -26 modifier at facility |
The most common EMG billing error: billing more muscle code units than documented needle insertions in the procedure note. If the note documents 5 muscles examined but the billing team submits 7 units, the discrepancy creates both a denial and a compliance exposure when audited against the procedure record.
Problem 3: Infusion Billing Sequencing
Neurology has a high concentration of infusion-treated conditions: multiple sclerosis (natalizumab, ocrelizumab), myasthenia gravis (IVIG), migraine (DHE infusion), and various other conditions requiring IV treatment. Infusion billing uses a tiered administration code set where the first substance billed as the primary determines the sequencing for all other substances in the same session.
The error: billing the secondary or sequential substance as the primary. This affects reimbursement for every subsequent code in the session. A $12,000 infusion session billed with incorrect sequencing may process at $7,000 — not a denial that generates a CO code, but a systematic underpayment on every infusion encounter that follows the same pattern.
The J-code (drug billing) layer adds additional complexity: infusion drugs are billed by units at specific drug-specific J-codes, updated annually by CMS. An outdated J-code generates a CO-4 denial on the drug portion while the administration component pays — meaning every infusion claim for that drug is partially denied until the J-code is corrected.
Frequently Asked Questions
Why does neurology have the highest denial rate?
Three factors: high prior authorization burden on expensive procedures (auth failures create high-value denials), complex coding for diagnostic procedures like EEG/EMG (documentation must precisely match codes billed), and infusion billing complexity with J-code and administration sequencing requirements. All three create denial patterns that compound when not managed by a specialty-trained biller.
How do you bill for botox injections in neurology?
Botulinum toxin injections for chronic migraine (CPT 64615) and spasticity (64642–64645) require prior authorization from most commercial payers and Medicare Advantage plans. Bill the injection code plus the drug (J0585 for onabotulinumtoxinA per unit). Number of units must match the documented dose. Medicare Part B covers migraine indication under specific LCD criteria — documentation must establish chronic migraine (15+ headache days/month) to pass medical necessity review.
What is the average neurology claim denial rate?
Neurology’s average denial rate is 20–30%, compared to 10–15% for most outpatient specialties. The average denied claim value in neurology is approximately $14,000 — significantly higher than most specialties due to the concentration of high-cost procedures and infusion therapies. This combination makes systematic denial prevention more financially critical in neurology than almost any other specialty.
See our neurology billing services — or start the free pilot.
Related Resources
Neurology billing specialists | Prior authorization guide | Systematic denial reduction
Our neurology billing specialists handle EEG/EMG coding and the prior authorization load that drives neurology’s 20-30% denial rate. We serve neurology practices in New York, California, and Pennsylvania.